Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07468136 · ClinicalTrials.gov registry record · Phase 1
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
A Phase 1 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT07468136: Recruiting Phase 1 study, sponsored by Mayo Clinic.
NCT07468136 is a Phase 1 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07468136, a Phase 1 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitors. It works by blocking the action of a substance that signals tumor cells to multiply. This helps stop or slow the spread of tumor cells. Giving retifanlimab with or without DFMO mat be safe, tolerable and/or effective in treating patients with progressive high grade glioma.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Lumbar Puncture
- PROCEDURE Magnetic Resonance Imaging
- DRUG Eflornithine
- BIOLOGICAL Retifanlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2030-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07468136
The ClinicalTrials.gov registry entry for NCT07468136 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07468136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07468136 about?
NCT07468136 is a clinical study titled "Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas". This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab...
What is the current status of trial NCT07468136?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2026-06-23. Estimated completion is 2030-10-25.
What interventions are being tested in trial NCT07468136?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Lumbar Puncture (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Eflornithine (DRUG), Retifanlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07468136?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.